MARK1 抗体
-
- 抗原 See all MARK1 抗体
- MARK1 (MAP/microtubule Affinity-Regulating Kinase 1 (MARK1))
-
适用
- 人, 小鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This MARK1 antibody is un-conjugated
-
应用范围
- Immunohistochemistry (IHC)
- 纯化方法
- Affinity purification
- 免疫原
- Recombinant fusion protein of human MARK1 (NP_061120.3).
- 亚型
- IgG
- Top Product
- Discover our top product MARK1 Primary Antibody
-
-
- 应用备注
- IHC 1:50-1:200
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Avoid freeze / thaw cycles.
-
- 抗原
- MARK1 (MAP/microtubule Affinity-Regulating Kinase 1 (MARK1))
- 别名
- MARK1 (MARK1 产品)
- 别名
- MGC80341 antibody, MARK1 antibody, AW491150 antibody, B930025N23Rik antibody, Emk3 antibody, Par-1c antibody, mKIAA1477 antibody, mPar-1c antibody, MARK antibody, Par1c antibody, MAP/microtubule affinity-regulating kinase 1 S homeolog antibody, microtubule affinity regulating kinase 1 antibody, MAP/microtubule affinity-regulating kinase 1 antibody, MAP/microtubule affinity regulating kinase 1 antibody, mark1.S antibody, MARK1 antibody, mark1 antibody, Mark1 antibody
- 背景
- MAP/microtubule affinity-regulating kinase 1 (MARK1) is a 795 amino acid protein belonging to the CAMK Ser/Thr protein kinase family. MARK1 is thought to play a role in the stability of the microtubule matrix of the cytoskeleton. MARK1 is activated by phosphorylation of Thr215 by LKB1 in complex with STRAD and MO25. Localized to the cytoskeleton, MARK1 contains one kinase-associated (KA1) domain, one protein kinase domain and one UBA domain. Expressed as three isoforms produced by alternative splicing, MARK1 is found with highest levels in brain, skeletal muscle and heart.
- 分子量
-
Observed_MW: 95kDa
Calculated_MW: 72kDa/84kDa/89kDa
- 基因ID
- 4139
- UniProt
- Q9P0L2
- 途径
- SARS-CoV-2 Protein Interactome, The Global Phosphorylation Landscape of SARS-CoV-2 Infection
-